A clinical and electrophysiological study of the effects of modified release 4-aminopyridine on upper limb impairment in Multiple Sclerosis

缓释4-氨基吡啶对多发性硬化症上肢损伤影响的临床和电生理研究

• 批准号: nhmrc : 1056294
• 负责人: Dr Marion Simpson
• 金额: $ 8.21万
• 依托单位: The University of Melbourne
• 依托单位国家: 澳大利亚
• 项目类别: Postgraduate Scholarships
• 财政年份: 2013
• 资助国家: 澳大利亚
• 起止时间: 2013-01-01 至 2018-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/clinical-electrophysiological-study-multiple-sclerosis/112541
• 关键词: clinical; electrophysiological; study; effects; modified

Multiple sclerosis (MS) is a common and disabling neurological disease affecting thousands of young Australians. In 2011 Fampridine received TGA approval for walking impairment in MS, but its mechanism of action is unknown and its effects on domains other than lower limb function remain untested. Our study will test whether Fampridine improves upper limb impairment in MS patients and will use electrophysiological measures of central nervous system conduction to uncover its mechanism of action.

多发性硬化症（MS）是一种常见的致残性神经系统疾病，影响着成千上万的澳大利亚年轻人。 2011 年，Fampridine 获得 TGA 批准用于治疗多发性硬化症的步行障碍，但其作用机制尚不清楚，并且其对下肢功能以外的领域的影响仍未经过测试。我们的研究将测试 Fampridine 是否能改善多发性硬化症患者的上肢损伤，并将利用中枢神经系统传导的电生理学测量来揭示其作用机制。